Dr Lilburn has a broad background with degrees in Medical Physics and Bioengineering, Computing and MRI with higher training in Clinical Nuclear Medicine. Focused on technique development and promotion covering diverse imaging biomarkers with PET/SPECT tracers and novel MRI sequences and contrast agents (hyperpolarized gas, USPIO, Manganese). Current work involves developing PET/MRI and Total Body PET quantitative measurements of oncological treatment response (mainly colorectal and neuro-oncology), pulmonary fibrosis, neurodegeneration and epilepsy.